Connect with us
Information

NORTH AMERICA EDITION
Australia
North America
World

Investing News NetworkYour trusted source for investing success

NORTH AMERICA EDITION
North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

Company Profiles Market

Company Profiles News

Company Profiles Stocks

Company Profiles Market
Company Profiles News
Company Profiles Stocks

Clene Inc.

NASDAQ:CLNN

Featured Articles and Interviews

More Featured Articles and Inverviews

Press Releases

Dec 12, 2022

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

Nov 28, 2022

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

Nov 07, 2022

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

More Press Releases

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Go Deeper

AI Powered

Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks of 2025

About InvestingNews.com

Interactive Chart

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.